Abstract:Background: Hepatocellular Carcinoma (HCC) is a major form of liver cancer and a leading cause of cancer-related death worldwide. New insights into HCC pathobiology and mechanism of drug actions are urgently needed to improve patient outcomes. HCC undergoes metabolic reprogramming of glucose metabolism from respiration to aerobic glycolysis, a phenomenon known as the 'Warburg Effect' that supports rapid cancer cell growth, survival, and invasion. mTOR is known to promote Warburg Effect, but the underlying mechanism(s) remains poorly defined. The aim of this study is to understand the mechanism(s) and significance of mTOR regulation of aerobic glycolysis in HCC. Methods: We profiled mTORC1-dependent long non-coding RNAs (lncRNAs) by RNA-seq of HCC cells treated with rapamycin. Chromatin immunoprecipitation (ChIP) and luciferase reporter assays were used to explore the transcriptional regulation of NEAT1 by mTORC1. [U-13C]-glucose labeling and metabolomic analysis, extracellular acidification Rate (ECAR) by Seahorse XF Analyzer, and glucose uptake assay were used to investigate the role of mTOR-NEAT1-NONO signaling in the regulation of aerobic glycolysis. RNA immunoprecipitation (RIP) and NONO-binding motif scanning were performed to identify the regulatory mechanism of pre-mRNA splicing by mTOR-NEAT1. Myristoylated AKT1 (mAKT1)/NRASV12-driven HCC model developed by hydrodynamic transfection (HDT) was employed to explore the significance of mTOR-NEAT1 signaling in HCC tumorigenesis and mTOR-targeted therapy. Results: mTOR regulates lncRNA transcriptome in HCC and that NEAT1 is a major mTOR transcriptional target. Interestingly, although both NEAT1_1 and NEAT1_2 are down-regulated in HCC, only NEAT1_2 is significantly correlated with poor overall survival of HCC patients. NEAT1_2 is the organizer of nuclear paraspeckles that sequester the RNA-binding proteins NONO and SFPQ. We show that upon oncogenic activation, mTORC1 suppresses NEAT1_2 expression and paraspeckle biogenesis, liberating NONO/SFPQ, which in turn, binds to U5 within the spliceosome, stimulating mRNA splicing and expression of key glycolytic enzymes. This series of actions lead to enhanced glucose transport, aerobic glycolytic flux, lactate production, and HCC growth both in vitro and in vivo. Furthermore, the paraspeckle-mediated mechanism is important for the anticancer action of US FDA-approved drugs rapamycin/temsirolimus. Conclusions: These findings reveal a molecular mechanism by which mTOR promotes the 'Warburg Effect', which is important for the metabolism and development of HCC, and anticancer response of mTOR-targeted therapy.

Mtor And P70s6 Kinase Expression In Primary Liver Neoplasms

Mammalian target of rapamycin as a novel target in the treatment of hepatocellular carcinoma.

The Mtor Pathway is Associated with the Poor Prognosis of Human Hepatocellular Carcinoma

Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma

Morphoproteomic and Molecular Concomitants of an Overexpressed and Activated Mtor Pathway in Renal Cell Carcinomas

Roles of mTOR and p-mTOR in gastrointestinal stromal tumors.

Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma.

Mtor in Viral Hepatitis and Hepatocellular Carcinoma: Function and Treatment

Prognostic Value of Phosphorylated Mtor/rps6kb1 in Non- Small Cell Lung Cancer.

Mtorc1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.

Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies

A Novel Hepatocellular Carcinoma-Specific Mtorc1-Related Signature for Anticipating Prognosis and Immunotherapy

Activation of PI3K/AKT and MAPK Pathway Through a PDGFRβ-dependent Feedback Loop is Involved in Rapamycin Resistance in Hepatocellular Carcinoma.

Inhibition of Mtorc1 Signaling Sensitizes Hepatocellular Carcinoma Cells to Glycolytic Stress

Characterization of the Mtor Pathway in Renal Cell Carcinoma and Its Use in Predicting Patient Selection for Agents Targeting This Pathway

mTOR regulates aerobic glycolysis through NEAT1 and nuclear paraspeckle-mediated mechanism in hepatocellular carcinoma

Transient Mtor Inhibition Facilitates Continuous Growth Of Liver Tumors By Modulating The Maintenance Of Cd133+Cell Populations

Targeting the Mtor Regulatory Network in Hepatocellular Carcinoma: Are We Making Headway?

The Mtor Pathway is Frequently Activated in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis

Activation of the Mammalian Target of Rapamycin Signalling Pathway in Prostate Cancer and Its Association with Patient Clinicopathological Characteristics

Effect of rapamycin on mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma EC9706 cell line